Must be 12 to \< 18 years of age (where permitted by local regulation) with a body weight ≥ 40 kilograms (kg), or ≥ 18 and \< 75 years of age regardless of body weight, at the time of signing the informed consent form (ICF).
Must have ≥ 1 of the protocol-defined COVID-19 symptoms of moderate or severe, present within 24 hours prior to randomization.
Confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as determined by any SARS-CoV-2 test, collected ≤ 48 hours prior to randomization.
Must be randomized within 48 hours of COVID-19 symptom onset, defined as the time when the first COVID-19 symptom occurs.
Agrees not to participate in another clinical study for the treatment of COVID-19 until completion of the study.
You may not be if
Current need or anticipated need for hospitalization within 24 hours, due to signs of severe COVID-19 illness or due to other medical conditions requiring hospitalization in the opinion of the site investigator.
Documented respiratory infection (for example, influenza, respiratory syncytial virus infection) other than COVID 19 within 14 days prior to the screening visit.
Known history of cirrhosis or liver decompensation (including ascites, variceal bleeding, or hepatic encephalopathy).
Suspected or confirmed COVID-19 outside of the current episode within 3 months of randomization.
Suspected or confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the investigational intervention.
Ongoing long COVID or postacute sequelae of COVID (PASC) diagnosis.
Current severely immunocompromised conditions.
Received or expected to receive any other COVID-19-specific therapies.
Have previously received secutrelvir.
Exposed to an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to the screening visit.
Clareo Health | Study of Secutrelvir in Participants With COVID-19
